China’s Haisco Pharmaceutical Group has entered a $2.9 billion licensing and research collaboration with Eli Lilly to develop innovative medicines across multiple therapeutic areas. Haisco will focus on discovering up to five target programs, while Lilly will handle clinical development and commercialization. The agreement allows Lilly exclusive rights to certain programs globally, while Haisco retains rights within its territory. Haisco could earn up to $87 million in initial payments, with additional milestones and royalties tied to product sales, marking a significant partnership between the two companies.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biospectrumasia.com/news/26/27732/chinas-haisco-pharma-inks-2-9-b-deal-with-eli-lilly-focusing-on-multiple-therapeutic-areas.html
